• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

False claims at Abbott

anonymous

Guest
Anyone else noticing how Abbott’s been running things lately? The lengths they go to push these products onto formularies is unreal. Marketing’s out there using materials that haven’t even been approved, MSLs are out hyping up their credentials and compatibility claims that don’t hold water, all just to get government programs like Medicaid and Medicare to bite.

What gets me is when concerns are actually raised about all this shady stuff, it’s like management just brushes it off. The people pulling these stunts are practically celebrated DVPs and senior directors patting them on the back like they’re heroes. Meanwhile, anyone with a conscience is left in the dust.

Feels like a ticking time bomb. We’ve all seen companies get nailed with FCA violations for this kind of thing, but here it’s just business as usual. Anyone else seeing how out of control this is getting?